Payment overview · 2025
General Payments
$1,857.27
105 reported records · 20 companies
Healthcare provider profile · identity verified
Daniel B Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · CULLMAN, AL · NPI 1629093638
Verified facts
What the public records show
CMS Open Payments records show Daniel B Williams, MD received $1,857.27 in general payments during 2025 across 105 reported records.
ABBVIE INC. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $568.95 | 30.6% | 31 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $182.25 | 9.8% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.75 | 7.6% | 10 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $99.90 | 5.4% | 6 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $95.70 | 5.2% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $88.22 | 4.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.88 | 4.7% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $79.69 | 4.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.05 | 4.2% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $70.93 | 3.8% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $66.82 | 3.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.00 | 3.1% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $48.35 | 2.6% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.57 | 2.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.38 | 1.9% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $34.57 | 1.9% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $27.88 | 1.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.70 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.21 | 1.0% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.47 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,857.27 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $323.19 | 18 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $119.45 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $105.80 | 6 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $99.90 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $95.70 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $94.12 | 9 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $88.22 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $79.69 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.05 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $70.93 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.90 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.90 | 5 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $66.82 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.28 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.00 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $55.58 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $46.08 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.30 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $34.57 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $27.88 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.30 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $11.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 208 | 44 |
| Gabapentin | Gabapentin | 181 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 86 |
| Clonazepam | Clonazepam | 125 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 113 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 22 |
| Dexamethasone | Dexamethasone | 89 | 64 |
| Tramadol Hcl | Tramadol Hcl | 89 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 88 | 17 |
| Azelastine Hcl | Azelastine Hcl | 84 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 25 |
| Famotidine | Famotidine | 71 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 24 |
| Lorazepam | Lorazepam | 62 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 58 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 22 |
| Potassium Chloride | Potassium Chloride | 50 | 18 |
| Metformin Hcl Er | Metformin Hcl | 45 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 34 |
| Ezetimibe | Ezetimibe | 42 | 15 |
| Meloxicam | Meloxicam | 42 | 19 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 17 |
| Temazepam | Temazepam | 42 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 40 | 17 |
| Ondansetron Odt | Ondansetron | 39 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 14 |
| Montelukast Sodium | Montelukast Sodium | 37 | 14 |
| Omeprazole | Omeprazole | 37 | 12 |
| Celecoxib | Celecoxib | 35 | 14 |
| Fluconazole | Fluconazole | 35 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 15 |
| Lisinopril | Lisinopril | 34 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | 22 |
| Sertraline Hcl | Sertraline Hcl | 31 | 11 |
| Nabumetone | Nabumetone | 30 | 21 |
| Azithromycin | Azithromycin | 28 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 27 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 27 | 24 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 23 |
| Metformin Hcl | Metformin Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Furosemide | Furosemide | 23 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Losartan Potassium | Losartan Potassium | 21 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 13 |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | 11 |
| Vyvanse | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Cephalexin | Cephalexin | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,857.27 · 105 records | ABBVIE INC. | ACTHAR, BENLYSTA, BREZTRI, Bimzelx, DALVANCE, EVENITY, FARXIGA, HADLIMA, JATENZO, KEVZARA, KRYSTEXXA, Kerendia, MOUNJARO, NP Thyroid 60, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, RENFLEXIS, REPATHA, REXULTI, RINVOQ, Rybelsus, SAPHNELO, SKYRIZI, STRENSIQ, SUBLOCADE, TEFLARO, TRELEGY ELLIPTA, TREMFYA, TRINTELLIX, UBRELVY, VRAYLAR, XYOSTED, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error